PDCD1 and hepatocellular carcinoma: In China, 217 HCC patients intolerant of first-line treatment or with progressive disease were treated with SHR-1210 (camrelizumab, a fully humanized anti-PD-1 immunoglobulin G4 [IgG4] monoclonal antibody) as second-line treatment (64).